ROYALTY PHARMA PLC: Diferență între versiuni
Admin (discuție | contribuții) Fără descriere a modificării |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 1: | Linia 1: | ||
Pagina dedicata companiei ROYALTY PHARMA PLC listata cu simbolul US.RPRX | Pagina dedicata companiei ROYALTY [[PHARMA]] PLC listata cu simbolul US.RPRX | ||
==Descriere companie== | ==Descriere companie== | ||
Versiunea curentă din 3 octombrie 2024 05:34
Pagina dedicata companiei ROYALTY PHARMA PLC listata cu simbolul US.RPRX
Descriere companie[edit | ]
Royalty Pharma plc (https://www.royaltypharma.com) is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.
Grafic actiuni companie[edit | ]